{"id":10318,"date":"2025-07-23T07:26:38","date_gmt":"2025-07-23T06:26:38","guid":{"rendered":"https:\/\/www.shs-capital.eu\/?p=10318"},"modified":"2025-07-24T10:02:51","modified_gmt":"2025-07-24T09:02:51","slug":"rotop-receives-marketing-authorisation-for-its-drug-rotecpsma-in-the-united-kingdom","status":"publish","type":"post","link":"https:\/\/www.shs-capital.eu\/rotop-receives-marketing-authorisation-for-its-drug-rotecpsma-in-the-united-kingdom\/","title":{"rendered":"ROTOP receives marketing authorisation for its diagnostic product RoTecPSMA\u00ae in the United Kingdom."},"content":{"rendered":"\n<p>We are delighted that the new product RoTecPSMA\u00ae from our portfolio company ROTOP has received marketing authorisation in the UK.<\/p>\n\n\n\n<p>RoTecPSMA\u00ae is a diagnostic kit that uses technetium-99m and has been specially developed for SPECT imaging in prostate cancer patients. It is the first PSMA SPECT tracer to be approved in a European country. It closes an important gap in care and makes advanced diagnostics more accessible for prostate cancer patients. Access to PSMA imaging is a key prerequisite for PSMA radioligand therapy yet remains severely limited in many countries.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.rotop-pharmaka.de\/blog\/2025\/04\/16\/first-marketing-authorization-for-rotechpsma\/\" data-type=\"link\" data-id=\"https:\/\/www.rotop-pharmaka.de\/blog\/2025\/04\/16\/first-marketing-authorization-for-rotechpsma\/\" target=\"_blank\" rel=\"noreferrer noopener\">Read the full article here.<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We are delighted that the new product RoTecPSMA\u00ae from our portfolio company ROTOP has received marketing authorisation in the UK. RoTecPSMA\u00ae is a diagnostic kit that uses technetium-99m and has been specially developed for SPECT imaging in prostate cancer patients. It is the first PSMA SPECT tracer to be approved in a European country. It [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":10323,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[91],"tags":[],"class_list":["post-10318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-shs-news-de"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/posts\/10318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/comments?post=10318"}],"version-history":[{"count":0,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/posts\/10318\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/media\/10323"}],"wp:attachment":[{"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/media?parent=10318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/categories?post=10318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.shs-capital.eu\/wp-json\/wp\/v2\/tags?post=10318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}